Avenue Therapeutics, Inc. (ATXI)
| Market Cap | 25.34M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -3.97M |
| Shares Out | 16.56M |
| EPS (ttm) | -0.24 |
| PE Ratio | n/a |
| Forward PE | 17.99 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 45,004 |
| Open | 1.54 |
| Previous Close | 1.55 |
| Day's Range | 1.51 - 1.56 |
| 52-Week Range | 1.50 - 11.58 |
| Beta | 0.60 |
| Analysts | Buy |
| Price Target | 12.00 (+684.3%) |
| Est. Earnings Date | Nov 3, 2021 |
About ATXI
Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain. The company was incorporated in 2015 and is based in New York, New York.
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for ATXI stock is "Buy." The 12-month stock price forecast is 12.00, which is an increase of 684.31% from the latest price.
News
Why Novavax, Orphazyme, Avenue Therapeutics Shares Are Moving Monday
Novavax, Inc. (NASDAQ: NVAX), Orphazyme A/S (NASDAQ: ORPH) and Avenue Therapeutics, Inc. (NASDAQ: ATXI) are among the biggest movers among biopharma stocks Monday. Novavax Finally Releases Phase 3 COVID...
Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol
NEW YORK, June 14, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced ...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avenue Therapeutics, Inc. - ATXI
New York, New York--(Newsfile Corp. - April 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Avenue Therapeutics Inc. ("Avenue" or the "Company") (NASDAQ: ATXI). Such investor...
Avenue Therapeutics (ATXI) Sees Hammer Chart Pattern: Time to Buy?
Avenue Therapeutics (ATXI) has been struggling lately, but the selling pressure may be coming to an end soon
Avenue Therapeutics Announces that the FDA is Still Reviewing Its NDA Resubmission for IV Tramadol
The FDA Has Not Provided a Decision Regarding the NDA The FDA Has Not Provided a Decision Regarding the NDA
Avenue Therapeutics Announces Publication of Real-World Data on Nonmedical Use of Tramadol in ASI-MV Network
NEW YORK, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (Avenue), a company focused on the development of intravenous (IV) tramadol for the U.S. market, today announced that...
Avenue Therapeutics Announces Publication of Tramadol Non-Medical Use in Four European Countries: A Comparative Analysis
NEW YORK, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (Avenue), a company focused on the development of intravenous (IV) tramadol for the U.S. market, today announced that...
Avenue Therapeutics' Pain Drug Gets Complete Response Letter
Avenue Therapeutics' (ATXI) NDA seeking an approval for its pipeline candidate tramadol to treat postoperative pain gets a CRL from the FDA, based on potential safety concerns. Shares down.
Avenue Therapeutics Sinks As FDA Rejects Opioid Pain Drug On Safety Concerns
Shares of micro-cap biopharma Avenue Therapeutics Inc (NASDAQ: ATXI) are plummeting on above-average volume after a binary event panned out against the company. What Happened: New York-based Avenue said...
Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol
Management to Host Conference Call at 8:30 a.m. ET Management to Host Conference Call at 8:30 a.m. ET
Avenue Therapeutics Announces Publication of a Review of IV Tramadol
NEW YORK, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announc...
Avenue Therapeutics (ATXI) Misses Earnings Estimates in Q2
Avenue Therapeutics (ATXI) reports a wider-than-expected loss in the second quarter of 2021.
Avenue Therapeutics Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights
NEW YORK, Aug. 14, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today reported...
What's in Store for Avenue Therapeutics (ATXI) in Q2 Earnings?
Avenue Therapeutics' (ATXI) sole pipeline candidate, tramadol, is under review. With lower clinical activities, operating expenses are likely to have declined during the second quarter.
Avenue Therapeutics, Inc. (ATXI) Dips More Than Broader Markets: What You Should Know
Avenue Therapeutics, Inc. (ATXI) closed the most recent trading day at $10.30, moving -1.9% from the previous trading session.
Avenue Therapeutics, Inc. (ATXI) Stock Sinks As Market Gains: What You Should Know
Avenue Therapeutics, Inc. (ATXI) closed the most recent trading day at $10.40, moving -1.61% from the previous trading session.
Avenue Therapeutics Announces Publication of Phase 3 Bunionectomy Study Results
Publication highlights IV tramadol 50 mg demonstrated a statistically significant benefit (p-value < 0.05) over placebo for primary and all key secondary efficacy endpoints Publication highlights IV tra...
Is Avenue Therapeutics (ATXI) Stock Outpacing Its Medical Peers This Year?
Is (ATXI) Outperforming Other Medical Stocks This Year?
Avenue Therapeutics, Inc. (ATXI) Upgraded to Strong Buy: Here's What You Should Know
Avenue Therapeutics, Inc. (ATXI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Avenue Therapeutics' Shares March Higher, Can It Continue?
As of late, it has definitely been a great time to be an investor in Avenue Therapeutics
Is Avenue Therapeutics (ATXI) Outperforming Other Medical Stocks This Year?
Is (ATXI) Outperforming Other Medical Stocks This Year?
5 Low-Beta Stocks to Beat Renewed Coronavirus Concerns
To combat market volatility, it is of utmost importance to create a portfolio of low-beta stocks.
4 Affordable Breakout Stocks for Stunning Returns
Selecting breakout stocks continue to be one of the most popular methods utilized by active investors.
Avenue Therapeutics Announces Publications in Peer-Reviewed Journals
NEW YORK, June 05, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announce...
Small Drug Industry Prospects Bright Amid Coronavirus Gloom
Small Drug Industry Prospects Bright Amid Coronavirus Gloom